Last reviewed · How we verify
Vincristine Liposomal
Vincristine Liposomal is a Small molecule drug developed by University of Southern California. It is currently in Phase 1 development. Also known as: Lipid-Encapsulated Vincristine, Liposomal Vincristine, Onco TCS, Vincacine.
At a glance
| Generic name | Vincristine Liposomal |
|---|---|
| Also known as | Lipid-Encapsulated Vincristine, Liposomal Vincristine, Onco TCS, Vincacine, VincaXome |
| Sponsor | University of Southern California |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Infections and infestations - Other, specify
- Neutrophil count decreased
- Alanine aminotransferase increased
- Febrile neutropenia
- Hyperglycemia
- Platelet count decreased
- Hypocalcemia
- White blood cell decreased
- Hyponatremia
- Peripheral sensory neuropathy
- Anemia
- Hypokalemia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristine Liposomal CI brief — competitive landscape report
- Vincristine Liposomal updates RSS · CI watch RSS
- University of Southern California portfolio CI
Frequently asked questions about Vincristine Liposomal
What is Vincristine Liposomal?
Vincristine Liposomal is a Small molecule drug developed by University of Southern California.
Who makes Vincristine Liposomal?
Vincristine Liposomal is developed by University of Southern California (see full University of Southern California pipeline at /company/university-of-southern-california).
Is Vincristine Liposomal also known as anything else?
Vincristine Liposomal is also known as Lipid-Encapsulated Vincristine, Liposomal Vincristine, Onco TCS, Vincacine, VincaXome.
What development phase is Vincristine Liposomal in?
Vincristine Liposomal is in Phase 1.
What are the side effects of Vincristine Liposomal?
Common side effects of Vincristine Liposomal include Infections and infestations - Other, specify, Neutrophil count decreased, Alanine aminotransferase increased, Febrile neutropenia, Hyperglycemia, Platelet count decreased.
Related
- Manufacturer: University of Southern California — full pipeline
- Also known as: Lipid-Encapsulated Vincristine, Liposomal Vincristine, Onco TCS, Vincacine, VincaXome
- Compare: Vincristine Liposomal vs similar drugs
- Pricing: Vincristine Liposomal cost, discount & access